Eurofins Scientific (ERFN) Stock Price & Analysis
ERFN Stock Chart & Stats
- Day’s Range
- MXN 1,440.00 - MXN 1,440.00
- 52-Week Range
- MXN 1,440.00 - MXN 1,440.00
- Previous Close
- MXN 1,440.00
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- MXN 323.89B
- Enterprise Value
- MXN 17.48B
- Total Cash (Recent Filing)
- MXN 618.00M
- Total Debt (Recent Filing)
- MXN 5.47B
- Price to Earnings (P/E)
- 29.2
- Beta
- 0.24
- Next Earnings
- Mar 02, 2027 (Est.)
- EPS Estimate
- 32.57
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 1.20%
Bulls Say, Bears Say
Bulls Say
Diversified Laboratory Platform
Eurofins operates across several regulated testing and scientific-services markets, reducing reliance on any single customer group or end market. Its broad laboratory network and wide test menu can support cross-selling, recurring compliance work, and resilience as demand shifts between industries.
Strong Revenue Expansion
The sharp 2025 revenue expansion indicates substantially stronger commercial momentum than in the preceding years. If supported by the company’s broad testing platform and market exposure, this larger revenue base can improve operating scale and provide more resources for continued laboratory and service development.
Positive Operating Cash Generation
Positive operating cash flow of approximately €1.30 billion demonstrates that Eurofins’ fee-for-service activities are converting into substantial cash from operations. This supports ongoing investment, debt servicing, and business development, even though free-cash-flow conversion remains below earlier levels.
Bears Say
Higher Financial Leverage
The large increase in debt-to-equity, alongside higher total debt and lower equity, materially reduces financial flexibility. Greater leverage raises refinancing and interest-burden exposure, potentially limiting Eurofins’ ability to fund acquisitions or absorb weaker operating performance without sacrificing other priorities.
Margin Deterioration And Volatility
The sustained decline in net margin and unusually low 2025 gross margin make profitability less predictable despite higher revenue. Unclear cost-structure or one-off effects could weaken earnings quality, constrain operating leverage, and make future profit growth more dependent on cost control than on sales expansion.
Weaker Free-cash-flow Conversion
Free cash flow declined even as revenue and absolute profits increased, while conversion fell from roughly 60% of net income in 2024 to 41%. This reduces internally generated funds for expansion and deleveraging, and indicates that capital spending or working-capital demands are absorbing more cash.
Eurofins Scientific News
ERFN FAQ
What was Eurofins Scientific’s price range in the past 12 months?
What is Eurofins Scientific’s market cap?
When is Eurofins Scientific’s upcoming earnings report date?
How were Eurofins Scientific’s earnings last quarter?
Is Eurofins Scientific overvalued?
Does Eurofins Scientific pay dividends?
What is Eurofins Scientific’s EPS estimate?
How many shares outstanding does Eurofins Scientific have?
What happened to Eurofins Scientific’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Eurofins Scientific?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Eurofins Scientific
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. It provides services, such as agroscience, including biological assessment, consumer and human, environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, including sustainability, audit, certification, quality inspection, QA-QC programme, and food and dietary supplement labelling services; biopharma, and clinical diagnostics. The company also offers consumer product testing, which include sustainability, testing, certifications and approvals, expert services and regulatory, inspections, audits, consumer research and sensory evaluation, and training courses; cosmetics and personal care; and electrical and electronics laboratories services. In addition, it provides environment testing, including maritime, water, air, soil, building material, pollution, waste, fuel/oil, microplastics, and radioactivity testing; and food and feed testing that include allergen, audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, GMO, heavy metal, melamine, microbiology, molecular biology, mycotoxin, nutritional analyses, organic contaminants, pesticide, veterinary drug, vitamin, and residual DNA testing. Further, the company provides forensic, genomic, maritime, materials and engineering, REACH, and sensory and consumer services, as well as in vitro diagnostics and PSS insourcing solutions. The company was founded in 1987 and is headquartered in Luxembourg, Luxembourg.
- Sector
- General
- Industry
- Medical - Diagnostics & Research
- CEO
- Gilles G. Martin
- Employees
- 65,000
- Website
- www.eurofins.com
- Address
- 23 Val Fleuri, Luxembourg City, LU, 1526, LU
Eurofins Scientific (ERFN) Earnings & Revenues
ERFN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 0 | 12 | 0 |
| Technical Analysis | 0 | 0 | 0 |
| Moving Averages | 0 | 12 | 0 |
